FcgRIIB, the only FcgR expressed on B cells, is important in the maintenance of immunological tolerance to self-Ags. In this study, we investigated the role of FcgRIIB in Ag-specific CD4 T cell tolerance induced by mucosally administered Ag (OVA) coupled to cholera toxin B subunit (Ag/CTB) or given alone. We found that sublingual administration of Ag/CTB conjugate or intragastric administration of a >100-fold higher dose of Ag alone efficiently suppressed parenteral immunization-induced Ag-specific T cell proliferation and delayed-type hypersensitivity responses in FcgRIIB-expressing wild-type (WT), but not O ral tolerance is known as a systemic immune unresponsiveness to a normally immunogenic parenteral injection of Ag induced by oral (or other mucosal) administration of the same Ag. Physiologically, oral tolerance may be important to avoid developing allergic responses to ingested food or inhaled environmental Ags. Experimentally, mucosal administration of selected autoreactive tissue Ags or allergens was found to induce peripheral tolerance that can prevent or ameliorate autoimmune and allergic inflammatory diseases; therefore, it has attracted attention as a possible means for Ag-specific immune therapy in such disorders (reviewed in Refs. 1, 2). Oral tolerance primarily affects effector T cells (Teffs), and Ab responses, in general, are not reduced significantly unless very high Ag doses are used for tolerization. High-dose tolerization may also lead to clonal depletion of T cells, in contrast to tolerization using lower Ag doses, which is mediated mainly by regulatory T cells (Tregs), both Foxp3 + and Foxp3 2 cells, suppressing the development and function of Teffs (1, 2). We (3-5) and other investigators (6-8) demonstrated that mucosal administration of various types of Ags coupled to cholera toxin B subunit (Ag/CTB) by either chemical conjugation or genetic fusion can more efficiently, and at .100-fold reduced dosages compared with Ag alone or Ag mixed with cholera toxin B subunit (CTB), induce peripheral T cell tolerance. Similar to other low-dose tolerance, this effect is associated with induction of Foxp3 + , as well as Foxp3 2 , Tregs (9). The coupling of Ag to CTB, which binds to GM1 ganglioside receptors present on many cell types, including all known APCs, strongly potentiates the mucosal tolerizing effect (10) by facilitating Ag transport across the mucosal barrier and, more importantly, increasing Ag uptake and presentation by APCs, such as dendritic cells (DCs), B cells, and macrophages (11, 12) . Recent work identified a previously poorly recognized role for B cells in immunological tolerance, including oral tolerance. Although it is well known that B cells can be pathological in autoimmune diseases by producing autoantibodies, recent studies showed that several experimentally induced autoimmune or inflammatory conditions, such as colitis (13), encephalitis (14), and collagen-induced arthritis (15), have a more aggressive course in B cell-deficient mice compared with normal mice that can be corrected by adoptive transfer of B cells (15, 16) . Studies showed that, under certain conditions, activated B cells can suppress Teff responses through providing signals, including IL-10 and TGF-b, which promote the development and expansion of Foxp3 + Tregs and/or Tr1 cells (16) (17) (18) (19) (20) . Consistent with a regulatory role for B cells, B cell-deficient mice have a defective ability to develop oral tolerance (21), as well as Tregs, in response to mucosal Ag administration, including Ag/CTB, which also can be corrected by adoptive transfer of B cells (10). Indeed, our studies (10, 22) showed that B cells play an especially important role as tolerogenic APCs after mucosal exposure to Ag/CTB conjugate, probably due to the fact that the majority of B cells, through the CTBmediated binding to GM1 ganglioside receptors, become effective Abbreviations used in this article: 7-AAD, 7-aminoactinomycin D; Ag/CTB, Ag (OVA) coupled to cholera toxin B subunit; B-TG mice, transgenic mice overexpressing FcgRIIB on B cells; B-NTG mice, littermate nontransgenic mice expressing normal wild-type levels of FcgRIIB on B
O ral tolerance is known as a systemic immune unresponsiveness to a normally immunogenic parenteral injection of Ag induced by oral (or other mucosal) administration of the same Ag. Physiologically, oral tolerance may be important to avoid developing allergic responses to ingested food or inhaled environmental Ags. Experimentally, mucosal administration of selected autoreactive tissue Ags or allergens was found to induce peripheral tolerance that can prevent or ameliorate autoimmune and allergic inflammatory diseases; therefore, it has attracted attention as a possible means for Ag-specific immune therapy in such disorders (reviewed in Refs. 1, 2). Oral tolerance primarily affects effector T cells (Teffs), and Ab responses, in general, are not reduced significantly unless very high Ag doses are used for tolerization. High-dose tolerization may also lead to clonal depletion of T cells, in contrast to tolerization using lower Ag doses, which is mediated mainly by regulatory T cells (Tregs), both Foxp3 + and Foxp3 2 cells, suppressing the development and function of Teffs (1, 2). We (3) (4) (5) and other investigators (6) (7) (8) demonstrated that mucosal administration of various types of Ags coupled to cholera toxin B subunit (Ag/CTB) by either chemical conjugation or genetic fusion can more efficiently, and at .100-fold reduced dosages compared with Ag alone or Ag mixed with cholera toxin B subunit (CTB), induce peripheral T cell tolerance. Similar to other low-dose tolerance, this effect is associated with induction of Foxp3 + , as well as Foxp3 2 , Tregs (9) . The coupling of Ag to CTB, which binds to GM1 ganglioside receptors present on many cell types, including all known APCs, strongly potentiates the mucosal tolerizing effect (10) by facilitating Ag transport across the mucosal barrier and, more importantly, increasing Ag uptake and presentation by APCs, such as dendritic cells (DCs), B cells, and macrophages (11, 12) . Recent work identified a previously poorly recognized role for B cells in immunological tolerance, including oral tolerance. Although it is well known that B cells can be pathological in autoimmune diseases by producing autoantibodies, recent studies showed that several experimentally induced autoimmune or inflammatory conditions, such as colitis (13) , encephalitis (14) , and collagen-induced arthritis (15) , have a more aggressive course in B cell-deficient mice compared with normal mice that can be corrected by adoptive transfer of B cells (15, 16) . Studies showed that, under certain conditions, activated B cells can suppress Teff responses through providing signals, including IL-10 and TGF-b, which promote the development and expansion of Foxp3 + Tregs and/or Tr1 cells (16) (17) (18) (19) (20) . Consistent with a regulatory role for B cells, B cell-deficient mice have a defective ability to develop oral tolerance (21) , as well as Tregs, in response to mucosal Ag administration, including Ag/CTB, which also can be corrected by adoptive transfer of B cells (10) . Indeed, our studies (10, 22) showed that B cells play an especially important role as tolerogenic APCs after mucosal exposure to Ag/CTB conjugate, probably due to the fact that the majority of B cells, through the CTBmediated binding to GM1 ganglioside receptors, become effective regulatory APCs for any contacted Ag coupled to CTB, irrespective of their BCR specificity.
In this study, we investigated the role of the IgG FcR FcgRIIB, and specifically its expression on B cells, in oral tolerance induced by mucosally administered Ag (OVA) conjugated to CTB or given alone. FcgRs constitute a family of surface molecules expressed on hematopoietic cells that can bind and be aggregated by the Fc domains of IgG immune complexes, thereby either stimulating or inhibiting cellular responses (23) . The inhibitory receptor FcgRIIB was found to play an important role both in the maintenance of immunological tolerance to self-Ags and in regulating immune responses to exogenous Ags (24) (25) (26) (27) (28) . Most cells of the myeloid lineage express both activating FcgRs and the inhibitory FcgRIIB; however, B cells only express FcgRIIB, which, dependent on its coligation with the BCR, controls the magnitude and persistence of the response to the Ag (23) . The significance of FcgRIIB-mediated negative regulation of immune responses has been established largely through the use of mice deficient in or having enhanced expression of this receptor (25) . FcgRIIB deficiency is associated with increased inflammation, allergy, and development of chronic autoimmunity (26, 29, 30) . Moreover, these knockout mice were described to display impaired mucosal tolerance after nasal administration of Ag (OVA), resulting in reduced suppression of eosinophilia and IgE production in murine allergic rhinitis and delayed-type hypersensitivity (DTH) reactions, which was assumed to reflect the lack of FcgRIIB expression on DCs (30, 31) . The role of FcgRIIB expressed on B cells in oral tolerance has not been examined.
In this study, using OVA as a model Ag, we show that FcgRIIB expression is critical for induction of Ag-specific oral tolerance after mucosal administration of high-dose free Ag, as well as lowdose Ag linked to CTB. Focusing on the latter system, we demonstrate that FcgRIIB-expressing B cells are both efficient and sufficient for induction of functional tolerance, as well as development of Foxp3 + Tregs, although partial tolerization (but not any increase in Tregs) could also be achieved in FcgRIIB-deficient mice after engraftment with FcgRIIB-expressing DCs.
Materials and Methods

Mice
Female 6-8-wk-old FcgRIIB-deficient mice on a pure C57BL/6 background were purchased from Taconic Europe (Ejby, Denmark). C57BL/6 female mice of similar age were also used (B & K Universal, Stockholm, Sweden) together with OT-IIxLy5.1 (CD45.1 + ) mice on a C57BL/6 background (kind gift from Dr. Mary Jo Wick, University of Gothenburg), which expressed a class II TCR specific for the peptide 323-339 fragment of OVA (OVAp) on nearly 50% of the CD4 + T cells. In addition, we used 6-8-wk-old female B cell-deficient mMT mice (kind gift from Dr. Nils Lycke, University of Gothenburg) on a C57BL/6 background. Transgenic mice overexpressing FcgRIIB on B cells (B-TG mice) and littermate nontransgenic mice expressing normal wild-type (WT) levels of FcgRIIB on B cells (B-NTG mice) were generated as previously reported (25) . Transgenic and gene-deficient mice were bred or kept under specific pathogen-free conditions at the experimental animal facility of the University of Gothenburg. The studies were approved by the University of Gothenburg Ethical Committee for Animal Experimentation.
Ags and conjugation of OVA to CTB
OVA protein (grade VII) was purchased from Sigma-Aldrich (St. Louis, MO), and OVAp (sequence ISQAVHAAHAEINEAGR) with .95% purity was obtained from TAG Copenhagen (Klampenborg, Denmark). Highly purified recombinant CTB was kindly provided by Crucell-Sweden (Stockholm, Sweden). OVA protein was chemically coupled to CTB using N-succininmidyl (3-[2-pyridyl]-dithio) propionate (Pierce Biotechnology, Rockford, IL) as a bifunctional coupling reagent, as described elsewhere (9) . The OVA/CTB conjugate was purified by fast protein liquid chromatography gel filtration on a Superdex 200 16/60 column (Pharmacia Biotech) using the BioLogic Workstation FPLC System (Bio-Rad, Richmond, CA). The purified conjugate was analyzed by ganglioside-monosialic acid (GM1) ELISA and shown to have strong GM1-binding activity, as well as high reactivity with Abs to either OVA or CTB (9) . The conjugate also had a strong capacity to induce OVA-specific T cell proliferation when tested on OT-II splenocytes; further, in the latter assays, the activity of the conjugate was not significantly inhibited by preincubation and coculture with polymyxin, but it was completely inhibited by preincubation and coculture with highly purified GM1 (a gift from the late Prof. Lars Svennerholm).
Mucosal tolerization and s.c. immunization
Mucosal administration of CTB/OVA conjugate for tolerization was given by the sublingual (s.l.) route using a well-established regimen (10) . In short, mice were given 10-ml s.l. doses of 40 mg OVA/CTB conjugate (or PBS as control) on three occasions at 2-d intervals. The extent of tolerization was tested by immunizing the mice, 2-d after the last s.l. dose, with s.c. injections in two dorsal positions on either side of the spine close to the tail with a total of 100 mg OVA emulsified in 100 ml CFA. As an alternative to the described standard low-dose s.l. tolerization regimen with OVA/CTB, mucosal high-dose tolerization was induced by a single administration of 20 mg OVA intragastrically in 0.3 ml 3% (w/v) sodium bicarbonate solution using a baby feeding catheter, and tolerization was tested as described for s.l. tolerization by Ag/CTB. + B cells (purity . 99%), at 10 6 cells/ml, were adoptively transferred to mice (see below) or incubated in vitro with 0.1 mg/ml OVA/CTB conjugate or OVA/CTB premixed with anti-OVA IgG (2.5 mg/ml; SigmaAldrich), 1 mg/ml OVA, or PBS for 1 h at 37˚C in 5% CO 2 , followed by two rounds of thorough washing with PBS and resuspension in PBS or medium (complete IMDM) to the desired cell concentration. CD11c + DCs were prepared by first digesting minced spleens and LNs of mice in 25 mg/ml Liberase and 400 U/ml DNase I (both from Roche Applied Science, Mannheim, Germany) at 37˚C for 30 min, followed by filtration through a nylon net and centrifugation. CD11c + DCs were isolated by positive selection using MACS MicroBeads coated with Ab against mouse CD11c (Miltenyi Biotec), according to the manufacturer's recommendation, and the DCs (purity .90%) were used in similar transfer and in vitro studies as described for the purified B cells.
T cell purification
Single-cell suspensions were prepared from spleens and LNs, as described above. CD4 + T cells were purified routinely by positive selection, or in cases requiring further isolation of CD25 + T cells, by negative selection. In either method, MACS MicroBeads labeled with various mAbs (Miltenyi Biotec) were used in accordance with the manufacturer's recommended protocol. Magnetic separation was performed with a positive selection column, according to the manufacturer's recommendation (Miltenyi Biotec). 
Adoptive transfer of cells
DTH test and preparation of cells from DTH-tested ears
After mucosal tolerization and 2 wk after the subsequent s.c. immunization, six mice in each group were given an intradermal (i.d.) injection in the left ear of 10 mg OVA in 20 ml PBS. The DTH reaction was monitored by measuring the ear thickness using a caliper meter (Mitutoyo) before and 24 h after the i.d. injection, and the differences were calculated and used as measures of DTH responses in a blinded fashion. Mice were sacrificed immediately after the ear thickness was measured, and single-cell suspensions of challenged ears were prepared by digesting minced ears in 25 mg/ml Liberase and 400 U/ml DNase I (both from Roche Applied Science) at 37˚C for 30 min, followed by filtration through a nylon net, centrifugation, and resuspension.
T cell proliferation and IFN-g assays
Single-cell suspensions from PLNs or spleen were prepared, and erythrocytes were removed by lysis. For studies of cell proliferation, 2 3 10 5 cells/well were cultured in a 200-ml volume of IMDM supplemented with 10% FCS, 1% L-glutamine, 1% gentamicin, and 50 mM 2-ME for 3 d in 96-well plates, with or without 0.2 or 1 mg/ml OVAp; or 2 or 10 mg/ml OVA. [ 
Statistical analysis
Results are expressed as mean 6 SEM. Unpaired Student t tests (twotailed) were used to calculate statistical differences between experimental and control groups.
Results
Mucosal administration of low-dose Ag/CTB conjugate or high-dose free Ag fails to induce oral tolerance in FcgRIIB 2/2 mice Sublingual tolerization with OVA/CTB. Previous studies showed that intragastric, s.l., or intranasal mucosal administration of OVA and other Ags in mice, given alone or with increased efficiency when linked to CTB, can induce peripheral T cell tolerance ("oral tolerance") along with Ag-specific Tregs (8, 9) . We examined whether FcgRIIB is required for such mucosal induction of tolerance, initially by comparing the effect on the development of DTH in FcgRIIB 2/2 mice and WT mice after s.l. mucosal administration of OVA/CTB conjugate. DTH is a typical T celldependent inflammatory response that is readily established by s.c. immunization with Ag, together with CFA, followed 2 wk later by an i.d. challenge with the same Ag. As shown in Fig. 1A , consistent with our previous findings (10), DTH (measured by ear thickness increase 24 h after i.d. challenge in the ear with OVA) was efficiently suppressed in WT mice that received three s.l. doses of OVA/CTB before a parenteral OVA/CFA immunization; in contrast, similarly treated FcgRIIB 2/2 mice showed no evidence of tolerance. Furthermore, infiltration of both total CD4 + T cells (data not shown) and Foxp3 2 CD4 + Teffs (Fig. 1B , Supplemental Fig. 1A ) was strongly reduced in challenged ears following s.l. administration of OVA/CTB to WT mice but not to FcgRIIB 2/2 mice. To determine whether the lack of mucosal tolerance in OVA/CTB-treated FcgRIIB 2/2 mice was associated with reduced development or infiltration of Tregs, we also examined Foxp3 + CD4 + Tregs in the challenged ears 24 h after DTH challenge. We found that s.l. treatment with OVA/CTB significantly increased the frequency of these cells in WT, but not FcgRIIB 2/2 , mice (Fig. 1C, Supplemental Fig. 1B ).
In parallel, we examined the PLN reaction of the mice following s.l. OVA/CTB treatment and s.c. immunization. Sublingual OVA/ CTB treatment prior to s.c. immunization significantly inhibited the proliferative response of PLN T cells from WT mice but not FcgRIIB 2/2 mice (Supplemental Fig. 2A ). The treatment also resulted in an increase in apoptotic PLN T cells from WT mice (Supplemental Fig. 2B ), a reduction in Foxp3 2 CD25 2 CD4 + Teffs (Supplemental Fig. 2C ), and an increase in Foxp3
+ Tregs (Supplemental Fig. 2D ), effects that were not seen in PLN cells from FcgRIIB 2/2 mice.
We also examined the levels of anti-OVA IgG Abs in serum 1 d before and 2 wk after the s.c. immunization with OVA in CFA.
Contrary to the T cell responses, no suppression of Ab responses was evident in either the WT or FcgRIIB 2/2 mice after the s.l. dose of OVA/CTB (data not shown).
FcgRIIB is also required for high-dose oral tolerance induction.
We also tested the importance of FcgRIIB for induction of oral tolerance after a single high-dose Ag administration. WT and FcgRIIB 2/2 mice were given an intragastric 20-mg dose of OVA, and 1 wk later the mice were immunized s.c. with OVA in CFA. Two weeks later, the mice were sacrificed, and PLN cells were examined in vitro for OVA-specific T cell proliferation and frequencies of Teffs and Tregs. The proliferation of PLN T cells from OVA-treated WT mice was markedly suppressed (by 73 6 1.3%) compared with cells from the PBS-treated controls, whereas the proliferation was increased in cells from similarly treated FcgRIIB + T cells from naive OT-IIxLy5.1 mice in the presence of OVAp, and examined OVA-specific T cell proliferation, IFN-g production, and induction of Tregs in the cultures. As shown in Fig. 4A and 4B, cells from OVA/CTB-treated WT mice suppressed in vitro T cell proliferation, whereas no such effect was seen using B cells from FcgRIIB 2/2 mice. Consistent with these findings, the levels of IFN-g production were reduced (Fig. 4B ) and OVA-specific Foxp3 + Tregs were increased (Fig. 4C the development of OVA-specific T cell responses, the recipient mice also received CD4 + OT-IIxLy5.1 T cells. Next, the mice received the standard three-dose s.l. treatment with OVA/CTB or PBS, followed by the initiation of DTH responses, as described above (Fig. 1) . Similarly treated WT and FcgRIIB mice that did not receive any WT B cells failed to respond to OVA/CTB-mediated tolerization and, thus, did not suppress either the Ag-specific DTH response (Fig. 5A ) or proliferation of PLN T cells (Fig. 5B) . In contrast, engrafting FcgRIIB 2/2 mice with WT B cells fully restored their capacity to suppress both of these responses after mucosal OVA/CTB treatment (Fig. 5A , 5B). Fur- thermore, PLN cells from these chimeric mice, similar to cells from WT mice, contained more Tregs following tolerization and immunization (Fig. 5C ). In addition, there was a marked decrease in the number of Ag-specific Teffs (Foxp3 2 CD25 2 CD4 + ) and an increase in apoptotic Ag-specific T cells (CD45.1 + Annexin V + 7-AAD 2 CD4 + ) in the PLNs of the chimeric mice (data not shown).
Increased tolerogenic effect of engraftment of B cell-deficient mMT mice with B cells overexpressing FcgRIIB compared with B cells expressing normal levels of FcgRIIB It is known that mMT mice, which lack B cells but contain other cell types, including DCs expressing normal levels of FcgRIIB, have a defective response to mucosal tolerization (10, 32, 33) . The data in Fig. 5 , showing that transfer of WT B cells to FcgRIIB 2/2 mice restored the ability of the latter mice to develop tolerance and Tregs in response to mucosal OVA/CTB administration, prompted us to investigate whether a similar transfer of FcgRIIBexpressing B cells to mMT mice would restore the induction of mucosal tolerance and Treg development in these mice after s.l. treatment with OVA/CTB. Further, we wished to determine whether transfer of B cells overexpressing FcgRIIB would be even more efficacious in these respects.
Therefore, CD19 + B cells were isolated from three strains of mice: B-TG mice (25), B-NTG mice, and FcgRIIB 2/2 mice not expressing any FcgRIIB. These isolated B cells, together with naive CD4 + OT-IIxLy5.1 T cells, were transferred i.v. into different groups of mMT mice that were subsequently treated with three s.l. doses of OVA/CTB or PBS, as previously described, followed by a s.c. immunization with OVA/CTB. Two weeks later, the mice were sacrificed, and their PLN cells were examined.
The results in Fig. 6A show that Ag re-encounter-stimulated T cell proliferation was strongly inhibited in PLN cells from the OVA/CTB-treated mMT mice that received B cells from either B-TG or B-NTG mice; this stood in sharp contrast to the complete lack of inhibition after transfer of B cells from OVA/CTB-treated (Fig. 3B, Supplemental Fig. 2B ). In this study, we show that tolerization of the chimeric mice, in addition to increasing Foxp3 + Tregs (Fig. 6C) , resulted in apoptosis of Teffs (Fig. 6D ) and an increase in LAP/TGF-b + CD4 + Tregs (Fig. 6E ) in the PLNs if the recipient mMT mice received B cells from either B-TG or B-NTG mice, with the former exhibiting the highest frequency of apoptotic T cells. As expected, no induction of Teff apoptosis (Fig.  6D) or LAP/TGF-b + CD4 + Tregs (Fig. 6E) was seen in the mice that received cells from FcgRIIB 2/2 mice.
We also investigated PLN cells from the recipient mice for their expression of the costimulatory/activation molecules CD80, CD83, and CD86 on B cells and DCs. Not surprisingly, PLN cells from mice that received B cells from FcgRIIB + OTIIxLy5.1 T cells, to either WT or mMT mice, followed by s.c. immunization of the mice with OVA in CFA. Two weeks later, the mice were sacrificed, and their PLN cells were analyzed; in addition, serum was collected and examined for Abs to OVA and CTB.
As shown in Fig. 7 and Supplemental Table I , OVA-stimulated T cell proliferation in vitro was suppressed in PLN cells from both WT and mMT mice that received WT B cells treated in vitro with OVA/CTB, and this effect was increased further when the donor B cells had been pretreated with OVA/CTB plus IgG anti-OVA Ab. The suppressive effects were more pronounced in WT mice compared with mMT mice as recipients (Fig. 7) , possibly owing to the fact that the WT mice, in contrast to the B cell-deficient mMT mice, had developed serum anti-OVA IgG Abs in response to the s.c. immunization (Supplemental Table I ), which may also form OVA/CTB-IgG complexes that could further promote the aggregation of FcgRIIB. In contrast, no suppression in T cell proliferation was seen in mice that received B cells from FcgRIIB 2/2 mice, irrespective of whether these cells had been treated with OVA/CTB alone or with OVA/CTB plus anti-OVA IgG; in fact, the T cell proliferation was increased in mMT mice (Fig. 7) . In addition, the serum levels of anti-OVA IgG were reduced in WT recipients that received WT B cells treated with OVA/CTB plus IgG anti-OVA Ab compared with controls, suggesting a partial tolerization of the OVA-specific Ab response as well (Supplemental Table I ).
DCs also require expression of FcgRIIB to induce T cell tolerance
Given the important role of the expression of FcgRIIB on B cells for mucosal induction of Ag-specific T cell tolerance, as well as the report by Samsom et al. (30) suggesting a similar role for FcgRIIB-expressing DCs, we tested, in a similar way as reported for B cells (Fig. 4) , the ability of DCs isolated from WT or FcgRIIB 2/2 mice after the standard three-dose s.l. treatment with OVA/CTB to suppress OVAp-specific Teffs and promote Tregs in vitro. The results in Fig. 8A show that Ag-specific T cell proliferation (left panel) and IFN-g production (middle panel) were mice with FcgRIIB-expressing WT DCs, much as in the same way as when such mice were engrafted with B cells (Fig. 5) , significantly restored their capacity to suppress both DTH (left panel) and T cell proliferative (middle panel) responses. Notably, however, there was no significant increase in Tregs in FcgRIIB 2/2 mice that received FcgRIIB-expressing DCs following tolerization and immunization (Fig. 8B, right panel) , which is in contrast with both OVA/CTB-treated WT mice (Fig. 8B, right panel) and FcgRIIB 2/2 mice engrafted with FcgRIIB-expressing B cells (Fig. 5C) . Moreover, at further difference from FcgRIIB 2/2 mice engrafted with WT B cells, there was no increase in apoptotic Ag-specific T cells (CD45.1 + Annexin V + 7-AAD 2 CD4 + ) in the PLNs of FcgRIIB 2/2 mice engrafted with WT DCs (data not shown).
Discussion
The pathways through which mucosally administered Ags induce oral tolerance remain incompletely understood, although the generation of Tregs inactivating Teffs has been identified as the main effector mechanism. Our recent work identified B cells as playing an important role as tolerogenic APCs in mucosally induced tolerization (10, 22) ; B cells appear to be especially prominent in lowdose T cell tolerance induced by mucosal administration of Ags linked to CTB, which latter molecule, through binding to the GM1 ganglioside receptor, can render most B cells effective tolerogenic APCs, irrespective of their BCR specificity. In this study, we found that the inhibitory IgG receptor FcgRIIB is critical for the induction of oral tolerance and that the expression of this receptor on Ag-presenting B cells is both important and sufficient for tolerance induction. Using OVA as a model Ag, we found that mucosal administration of either low doses of CTBlinked OVA or a high dose of OVA alone strongly suppressed parenteral immunization-induced OVA-specific T cell proliferation and DTH responses in FcgRIIB-expressing WT mice, but it completely failed to do so in FcgRIIB-deficient FcgRIIB 2/2 mice.
We confirmed a previous study (30) Purified B cells, pulse-treated with OVA/CTB in vitro and extensively washed before adoptive transfer to either WT or mMT mice, also conferred tolerance in WT mice, as well as in mMT mice, provided that the transferred Ag/CTB-treated B cells expressed FcgRIIB. mMT mice, apart from their lack of B cells, contain functional FcgRIIB-expressing DCs and other types of APCs (34) and yet they have a defective oral tolerance response unless adoptively receiving FcgRIIB-expressing B cells (21) . At the same time, as first described by Gonnella et al. (32) and confirmed by us (10), mMT mice normally can develop a reduced, modified form of tolerance in response to mucosally administered Ag, being mediated by Ag-specific Foxp3 2 LAP + Tregs rather than Foxp3 + cells (10) . It was reported that B cells can modulate the Ag presentation to T cells by DCs in mMT mice by promoting IL-4 production and decreasing IL-12 production, thus providing a more balanced Th1/Th2 response (35) . Based on this, the complete lack of oral tolerance after adoptive transfer of FcgRIIB addition, we found that adoptive transfer of FcgRIIB-expressing WT DCs to FcgRIIB 2/2 mice could restore the in vivo tolerogenic effect of Ag/CTB treatment in these mice, although apparently to a lesser extent than seen after transfer of FcgRIIB-expressing B cells; also different from the B cells, the transferred DCs failed to induce Ag-specific Foxp3 + Tregs in vivo. Normally, like other FcgRs, FcgRIIB is activated only after being cross-linked by IgG-Ag immune complexes (26, 36) . However, our results suggest that FcgRIIB on B cells may be activated by exposure to Ag/CTB, even in the absence of any IgG Ab, although the FcgRIIB-expressing B cells became even more effective in inducing tolerance and Tregs following treatment with IgG Ab immune-complexed Ag/CTB compared with Ag/CTB alone. It could be argued that when FcgRIIB-expressing WT mice were first mucosally treated with Ag/CTB and then parenterally immunized, they developed IgG Ab that could form immune complexes with the tolerizing Ag/CTB or immunizing Ag, thus providing a regulatory mechanism controlling Fcg-activating receptors by the ligation of FcgRIIB. However, this possibility is unlikely in mMT mice completely devoid of IgG because the adoptive transfer of OVA/CTB-pretreated FcgRIIB-expressing B cells significantly suppressed the T cell response to a subsequent parenteral immunization with OVA in CFA (Fig. 7) . Furthermore, ELISA analyses confirmed the complete lack of detectable IgG anti-OVA or anti-CTB Abs in sera from these mice also after immunization (Supplemental Table I ). It remains to be determined by which mechanism the CTB-linked Ag can activate FcgRIIB on B cells in the absence of IgG Ab and render the B cells tolerogenic; studies are in progress to determine possible direct interactions between CTB-bound GM1 ganglioside receptors and FcgRIIB on the B cell surface, as well as the in vitro activation of cytoplasmic tyrosine inhibitory motif and other downstream molecules in FcgRIIB-expressing B cells exposed to Ag/CTB conjugate and/or CTB alone. In this regard, it is noteworthy that Floto et al. (37) found that the inhibitory function of FcgRIIB depends on its aggregation and integration into cell membrane lipid rafts, which also could be induced in vitro in the absence of IgG by treating FcgRIIB-expressing cells with PMA; it was found to result in colocalization of FcgRIIB with fluorescently labeled CTB, which is an established marker of lipid rafts.
APCs initiate either proinflammatory Teff or anti-inflammatory Treg responses, depending on their activation status, which is significantly controlled by autologous inhibitory signals generated via FcgRIIB. Samsom et al. (30) showed that the absence of FcgRIIB can convert tolerogenic T cell responses into immunogenic responses associated with increased IL-2 and IFN-g secretion, and they suggested that the disappearance of tolerance resulted from the production of proinflammatory cytokines, such as MCP-1, TNF-a, and IL-6, together with increased expression of costimulatory molecules by DCs lacking the inhibitory FcgRIIB (30) . Such a process, although mediated not only by DCs but also, and perhaps even more importantly, via FcgRIIB 2/2 B cells, is also suggested by our findings that mMT mice that adoptively received inhibitory signaling on non-B cell APCs, such as DCs, and increasing their propensity for stimulating Teff, rather than Treg, responses. These results may also suggest that the refractoriness of FcgRIIB-deficient mice to mucosal tolerization could result from abnormal baseline activation of APCs in these mice, which is normalized by the adoptive transfer of FcgRIIB-expressing B cells, and, to a lesser extent, by similar transfer of FcgRIIBexpressing DCs. In this regard, it is also worth noting that, as illustrated in Fig. 6 Finally, as mentioned above, although our results indicate that incubation of FcgRIIB-expressing B cells with Ag/CTB conjugate in the absence of any IgG was enough to render the B cells effectively tolerogenic, it is also clear that the tolerogenic effect was increased further by incubating the cells with IgG immunecomplexed Ag/CTB conjugate compared with Ag/CTB conjugate alone. This finding could have direct implications as a means to maximize the efficacy of B cells in cell therapy against autoimmune and related inflammatory diseases. We recently described, as was also evident in the current study, that a highly efficient way to generate tolerogenic B cells is by incubating naive B cells with a relevant Ag conjugated to CTB (22) . This allows most B cells, irrespective of BCR, to take up and present the CTB-linked Ag and induce their expression of LAP/TGF-b and, after adoptive transfer, their in vivo production of IL-10 as well (22) . Our previous study further suggested that B cells pulsed in vitro with relevant Ag/CTB conjugates may be used in cell therapy to induce Ag-specific suppression of autoimmune disease. Thus, adoptive transfer of B cells pulsed with an autoreactive myelin oligodendrocyte glycoprotein peptide conjugated to CTB prevented the development of experimental autoimmune encephalomyelitis and increased the number of Foxp3 + Tregs; similar effects were seen when B cells were given "therapeutically" to mice with earlystage experimental autoimmune encephalomyelitis (22) . Our present findings suggest that the protective effect against autoimmune and related inflammatory diseases that may be achieved by infusion of B cells pretreated in vitro with relevant Ag/CTB formulations can be increased further by adding an IgG Ab to the Ag/CTB formulation used for the in vitro treatment of B cells prior to the in vivo infusion.
